[go: up one dir, main page]

HK1144808A1 - Heterocyclic inhibitors of stearoyl-coa desaturase coa - Google Patents

Heterocyclic inhibitors of stearoyl-coa desaturase coa

Info

Publication number
HK1144808A1
HK1144808A1 HK10111248.5A HK10111248A HK1144808A1 HK 1144808 A1 HK1144808 A1 HK 1144808A1 HK 10111248 A HK10111248 A HK 10111248A HK 1144808 A1 HK1144808 A1 HK 1144808A1
Authority
HK
Hong Kong
Prior art keywords
coa
stearoyl
desaturase
heterocyclic inhibitors
heterocyclic
Prior art date
Application number
HK10111248.5A
Other languages
English (en)
Chinese (zh)
Inventor
Sultan Chowdhury
Natalie Dales
Julia Fonarev
Jianmin Fu
Duanjie Hou
Qi Jia
Vishnumurthy Kodumuru
Natalia Pokrovskaia
Shaoyi Sun
Zaihui Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40740143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1144808(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1144808A1 publication Critical patent/HK1144808A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10111248.5A 2008-02-20 2010-12-02 Heterocyclic inhibitors of stearoyl-coa desaturase coa HK1144808A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3013708P 2008-02-20 2008-02-20
PCT/EP2009/051926 WO2009103739A1 (en) 2008-02-20 2009-02-18 Heterocyclic inhibitors of stearoyl-coa desaturase

Publications (1)

Publication Number Publication Date
HK1144808A1 true HK1144808A1 (en) 2011-03-11

Family

ID=40740143

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10111248.5A HK1144808A1 (en) 2008-02-20 2010-12-02 Heterocyclic inhibitors of stearoyl-coa desaturase coa

Country Status (29)

Country Link
US (2) US8049016B2 (es)
EP (1) EP2245029B1 (es)
JP (2) JP5507474B2 (es)
KR (1) KR101584826B1 (es)
CN (1) CN102007123B (es)
AR (1) AR070429A1 (es)
AU (1) AU2009216769A1 (es)
BR (1) BRPI0907826A2 (es)
CA (1) CA2715947C (es)
CL (1) CL2009000381A1 (es)
CO (1) CO6290655A2 (es)
CR (1) CR11629A (es)
CU (1) CU23890B1 (es)
EA (1) EA022797B1 (es)
EC (1) ECSP10010411A (es)
HK (1) HK1144808A1 (es)
HN (1) HN2010001647A (es)
IL (1) IL207578A (es)
JO (1) JO3014B1 (es)
MA (1) MA32150B1 (es)
MX (1) MX2010009158A (es)
MY (1) MY156317A (es)
NZ (1) NZ587350A (es)
PE (1) PE20091473A1 (es)
SV (1) SV2010003650A (es)
TW (1) TWI457338B (es)
UA (1) UA105000C2 (es)
WO (1) WO2009103739A1 (es)
ZA (1) ZA201005725B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130036080A (ko) 2006-08-15 2013-04-09 제논 파마슈티칼스 인크. 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물
WO2008074835A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
UA105000C2 (uk) 2008-02-20 2014-04-10 Новартіс Аг ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
EP2483264A1 (en) * 2009-10-01 2012-08-08 Novartis AG Pyrazole derivatives which modulate stearoyl-coa desaturase
US9193723B2 (en) * 2012-05-11 2015-11-24 Abbvie Inc. NAMPT inhibitors
MX2014014253A (es) 2012-05-21 2015-02-17 Novartis Ag Novedosas n-piridinil-amidas sustituidas en el anillo como inhibidoras de cinasa.
WO2018045907A1 (zh) * 2016-09-08 2018-03-15 四川科伦博泰生物医药股份有限公司 一种新型2-酰氨基噻唑衍生物及其制备方法与用途
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
BR112019013954A2 (pt) 2017-01-06 2020-02-11 Yumanity Therapeutics, Inc. Métodos para o tratamento de distúrbios neurológicos
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
SG11202009280RA (en) 2018-03-23 2020-10-29 Yumanity Therapeutics Inc Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
CN114222732B (zh) * 2019-10-28 2023-04-04 南京明德新药研发有限公司 一种尿酸促排剂及其合成方法和其在医药上的应用
IL294052A (en) * 2019-12-20 2022-08-01 Tenaya Therapeutics Inc Fluoroalkyl-oxadiazoles and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH590267A5 (es) * 1972-10-04 1977-07-29 Ciba Geigy Ag
US4058617A (en) * 1972-10-04 1977-11-15 Ciba-Geigy Corporation Imidazoles and pharmaceutical composition
IL44282A (en) 1974-02-25 1979-01-31 Ciba Geigy Ag 1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
WO1999021555A2 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
WO2001074811A2 (en) 2000-03-30 2001-10-11 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
EP1354603A1 (en) 2000-12-26 2003-10-22 Takeda Chemical Industries, Ltd. Concomitant drugs
EP1402900A1 (en) 2001-06-11 2004-03-31 Takeda Chemical Industries, Ltd. Medicinal compositions
US20090192191A1 (en) 2004-01-09 2009-07-30 Braj Bhushan Lohray Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CN101083994A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
CN101083992A (zh) * 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
MX2007015216A (es) * 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
PL2029572T3 (pl) * 2006-06-05 2011-05-31 Novartis Ag Związki organiczne
KR20130036080A (ko) * 2006-08-15 2013-04-09 제논 파마슈티칼스 인크. 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물
KR20090040478A (ko) 2006-08-24 2009-04-24 노파르티스 아게 ２-(피라진-２-일)-티아졸 및 ２-(１Ｈ-피라졸-３-일)-티아졸 유도체, 및 대사, 심혈관 및 기타 장애의 치료를 위한 스테아로일-ＣｏＡ 데새투라제(ＳＣＤ) 억제제로서의 관련 화합물
CA2662574A1 (en) * 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
GB0621452D0 (en) * 2006-10-27 2006-12-06 Ucl Business Plc Therapy for liver disease
WO2008074835A1 (en) * 2006-12-20 2008-06-26 Novartis Ag 2-substituted 5-membered heterocycles as scd inhibitors
CA2714591A1 (en) * 2008-02-13 2009-08-20 Eisai R&D Management Co., Ltd. Bicycloamine derivative
UA105000C2 (uk) 2008-02-20 2014-04-10 Новартіс Аг ГЕТЕРОЦИКЛІЧНІ ІНГІБІТОРИ СТЕАРОЇЛ-СоА-ДЕСАТУРАЗИ
KR20110022089A (ko) 2008-06-27 2011-03-04 노파르티스 아게 유기 화합물

Also Published As

Publication number Publication date
ZA201005725B (en) 2011-04-28
TWI457338B (zh) 2014-10-21
SV2010003650A (es) 2011-07-05
US8318949B2 (en) 2012-11-27
JP5507474B2 (ja) 2014-05-28
WO2009103739A1 (en) 2009-08-27
IL207578A (en) 2014-11-30
MY156317A (en) 2016-02-15
EP2245029A1 (en) 2010-11-03
NZ587350A (en) 2012-07-27
CR11629A (es) 2010-11-16
AR070429A1 (es) 2010-04-07
KR20100117677A (ko) 2010-11-03
JP5813162B2 (ja) 2015-11-17
BRPI0907826A2 (pt) 2019-12-10
CA2715947C (en) 2016-10-25
PE20091473A1 (es) 2009-10-23
EA201001315A1 (ru) 2011-06-30
MX2010009158A (es) 2010-09-24
CU20100170A7 (es) 2011-10-31
CU23890B1 (es) 2013-04-19
CN102007123A (zh) 2011-04-06
EA022797B1 (ru) 2016-03-31
ECSP10010411A (es) 2010-09-30
AU2009216769A1 (en) 2009-08-27
US20120014906A1 (en) 2012-01-19
TW200942534A (en) 2009-10-16
US8049016B2 (en) 2011-11-01
CA2715947A1 (en) 2009-08-27
KR101584826B1 (ko) 2016-01-18
MA32150B1 (fr) 2011-03-01
JP2014132025A (ja) 2014-07-17
IL207578A0 (en) 2010-12-30
EP2245029B1 (en) 2015-04-15
HN2010001647A (es) 2013-11-11
JP2011512384A (ja) 2011-04-21
CN102007123B (zh) 2014-04-30
JO3014B1 (ar) 2016-09-05
CL2009000381A1 (es) 2010-09-10
CO6290655A2 (es) 2011-06-20
US20090264444A1 (en) 2009-10-22
UA105000C2 (uk) 2014-04-10

Similar Documents

Publication Publication Date Title
HK1144808A1 (en) Heterocyclic inhibitors of stearoyl-coa desaturase coa
IL295518B1 (en) Heterocyclic compounds used as pdk1 inhibitors
IL208232A0 (en) Novel piperidine derivatives as inhibitors of stearoyl-coa desaturase
HRP20181370T1 (hr) Heterociklični spoj i njegova uporaba
IL213596A0 (en) Heterocyclic compounds and methods of use
ZA201700326B (en) Inhibitors of beta-secretase
EP2445885A4 (en) SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CHINESE INHIBITORS AND METHOD FOR THEIR USE
IL206704A0 (en) Fused heterocyclic derivatives and methods of use as c-met inhibitors
HK1157751A1 (en) Bridged heterocyclic compounds and methods of use
IL208233A0 (en) Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
IL201117A0 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2480081A4 (en) Bridged heterocyclic compounds and methods for their use
IL205505A0 (en) Inhibitors of stearoyl - coa desaturase
IL192557A0 (en) Substituted imidazole derivatives and their use as ptpase inhibitors
GB0621107D0 (en) Inhibitors of phosphodiesterase-4

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190221